 <h1>Aralen Side Effects</h1><p class="drug-subtitle"><b>Generic Name:</b> <i>chloroquine</i></p><ul class="ddc-anchor-links"><li>Consumer</li>
<li>Professional</li>
<li>FAQ</li></ul><p class="ddc-notification"><b>Note:</b> This document contains side effect information about chloroquine. Some of the dosage forms listed on this page <em>may not</em> apply to the brand name Aralen.</p><h2 class="ddc-anchor-offset" id="consumer">For the Consumer</h2><p><i>Applies to chloroquine: oral tablet</i></p><h3>Side effects requiring immediate medical attention</h3><p>Along with its needed effects, chloroquine (the active ingredient contained in Aralen) may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.</p><p>
<b>Check with your doctor immediately</b> if any of the following side effects occur while taking chloroquine:</p><p>
<i>Incidence not known</i>
</p><ul>
<li>Anxiety</li>
<li>attempts at killing oneself</li>
<li>back, leg, or stomach pains</li>
<li>black, tarry stools</li>
<li>bleeding gums</li>
<li>blistering, peeling, or loosening of the skin</li>
<li>blood in the urine or stools</li>
<li>blurred or decreased vision</li>
<li>change in near or distance vision</li>
<li>chest discomfort or pain</li>
<li>chills</li>
<li>cold sweats</li>
<li>confusion</li>
<li>continuing ringing or buzzing or other unexplained noise in the ears</li>
<li>cough</li>
<li>dark urine</li>
<li>diarrhea</li>
<li>difficulty in focusing the eyes</li>
<li>difficulty with speaking</li>
<li>difficulty with swallowing</li>
<li>disturbed color perception</li>
<li>dizziness</li>
<li>dizziness, faintness, or lightheadedness when getting up suddenly from a lying or sitting position</li>
<li>double vision</li>
<li>drooling</li>
<li>fast, slow, irregular, or pounding heartbeat</li>
<li>feeling that others are watching you or controlling your behavior</li>
<li>feeling that others can hear your thoughts </li>
<li>feeling, seeing, or hearing things that are not there</li>
<li>fever</li>
<li>general tiredness and weakness</li>
<li>halos around lights</li>
<li>headache</li>
<li>hearing loss</li>
<li>inability to move the eyes</li>
<li>increased blinking or spasms of the eyelid</li>
<li>joint or muscle pain</li>
<li>large, hive-like swelling on the face, eyelids, lips, tongue, throat, hands, legs, feet, or sex organs</li>
<li>light-colored stools</li>
<li>loss of balance control</li>
<li>lower back or side pain</li>
<li>muscle trembling, jerking, or stiffness</li>
<li>muscular pain, tenderness, wasting, or weakness</li>
<li>night blindness</li>
<li>nausea</li>
<li>overbright appearance of lights</li>
<li>painful or difficult urination</li>
<li>pale skin</li>
<li>pinpoint red spots on the skin</li>
<li>puffiness or swelling of the eyelids or around the eyes, face, lips, or tongue</li>
<li>red skin lesions, often with a purple center</li>
<li>red, irritated eyes</li>
<li>restlessness</li>
<li>shuffling walk</li>
<li>skin rash, hives, or itching</li>
<li>sore throat</li>
<li>sores, ulcers, or white spots on the lips or in the mouth</li>
<li>sticking out of the tongue</li>
<li>stiffness of the limbs</li>
<li>sweating</li>
<li>swollen or painful glands</li>
<li>tightness in the chest</li>
<li>trouble breathing</li>
<li>tunnel vision</li>
<li>twitching, twisting, or uncontrolled repetitive movements of the tongue, lips, face, arms, or legs</li>
<li>uncontrolled movements, especially of the face, neck, and back</li>
<li>unusual bleeding or bruising</li>
<li>unusual tiredness or weakness</li>
<li>upper right abdominal or stomach pain</li>
<li>vomiting</li>
<li>yellow eyes and skin</li>
</ul><p>
<i>Get emergency help immediately if any of the following symptoms of overdose occur while taking chloroquine:</i>
</p><p>
<i>Symptoms of overdose</i>
</p><ul>
<li>Cold, clammy skin</li>
<li>decreased urine</li>
<li>drowsiness</li>
<li>dry mouth</li>
<li>fast, weak pulse</li>
<li>increased thirst</li>
<li>lightheadedness, dizziness, or fainting</li>
<li>loss of appetite</li>
<li>muscle pain or cramps</li>
<li>numbness or tingling in the hands, feet, or lips</li>
</ul><h3>Side effects not requiring immediate medical attention</h3><p>Some side effects of chloroquine may occur that usually <b>do not need medical attention</b>. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects.</p><p>Check with your health care professional if any of the following side effects <b>continue or are bothersome</b> or if you have any questions about them:</p><p>
<i>Incidence not known</i>
</p><ul>
<li>Change in hair color</li>
<li>hair loss</li>
<li>increased sensitivity of the skin to sunlight</li>
<li>redness or other discoloration of the skin</li>
<li>severe sunburn</li>
<li>stomach cramps</li>
<li>trouble sleeping</li>
<li>weight loss</li>
</ul><p>
<!-- end oral tablet --><div class="related-links"><svg aria-hidden="true" class="ddc-icon ddc-icon-info" focusable="false" height="22" viewbox="0 0 24 24" width="22" xmlns="http://www.w3.org/2000/svg"><path d="M14 2H6c-1.1 0-1.99.9-1.99 2L4 20c0 1.1.89 2 1.99 2H18c1.1 0 2-.9 2-2V8l-6-6zm2 16H8v-2h8v2zm0-4H8v-2h8v2zm-3-5V3.5L18.5 9H13z"></path></svg> <span>Managing side effects <span class="ddc-text-nowrap">(general information)</span></span></div>
<h2 class="ddc-anchor-offset" id="professional">For Healthcare Professionals</h2><p><i>Applies to chloroquine: compounding powder, injectable solution, oral tablet</i></p><h3>Ocular</h3><p>Retinopathy and irreversible retinal damage have been reported during long-term, high-dose therapy.</p>
<p></p>
<p>Maculopathy and macular degeneration have been reported and may be irreversible.</p>
<p></p>
<p>Irreversible retinopathy with retinal pigmentation changes (bull's eye appearance) and visual field defects (paracentral scotomas) have been reported in patients receiving long-term or high-dose 4-aminoquinoline therapy.<sup>[Ref]</sup></p><p><b>Common</b> (1% to 10%): Transient blurred vision</p>
<p><b>Rare</b> (0.01% to 0.1%): Reversible corneal opacity, retinopathy, irreversible retinal damage</p>
<p><b>Frequency not reported</b>: Retinal degeneration, macular defects of color vision, pigmentation, optic atrophy, scotomas, blindness, corneal opacity, pigmented deposits, vision blurred/difficulty focusing, accommodation disorder, diplopia, field defects, double vision, decreased visual acuity, color-vision defects, pigmentary retinopathy, corneal deposits, keratopathy, decreased corneal sensitivity, corneal edema</p>
<p><b>Postmarketing reports</b>: Maculopathy, macular degeneration, visual disturbances (blurred vision, focusing/accommodation difficulty), nyctalopia, scotomatous vision with field defects of paracentral/pericentral ring types/typically temporal scotomas (e.g., difficulty in reading with words tending to disappear, seeing half an object, misty vision, fog before the eyes), reversible corneal opacities</p>
<p></p>
<p>4-aminoquinoline therapy:</p>
<p>-Postmarketing reports: Irreversible retinopathy with retinal pigmentation changes (bull's eye appearance), visual field defects (paracentral scotomas)<sup>[Ref]</sup></p><h3>Dermatologic</h3><p>Pruritus has been seen more commonly in Africans.  The onset was generally 6 to 48 hours after the first dose and antihistamines did not always control the pruritus.</p>
<p></p>
<p>Pigmentation disorder (including bluish-black pigmentation of the nails and mucosa) has been reported with long-term use.  Increased pigmentation of the skin and mucous membranes was generally of a bluish color was not always reversible on discontinuation.</p>
<p></p>
<p>Several cases of hypopigmentation of the skin have been reported.  Most of the patients described were African or of African descent with dark skin who had been exposed to the sun.  One was a Hispanic patient who developed vitiligo-like skin depigmentation after 1 month of therapy for cutaneous lupus erythematosus.  The skin rapidly repigmented after this drug was discontinued.</p>
<p></p>
<p>At least 2 cases of exacerbation of psoriasis requiring hospitalization have been reported.<sup>[Ref]</sup></p><p><b>Very common</b> (10% or more): Pruritus</p>
<p><b>Common</b> (1% to 10%): Skin eruptions, urticaria</p>
<p><b>Uncommon</b> (0.1% to 1%): Alopecia, pigmentation disorder (including bluish-black pigmentation of the nails and mucosa)</p>
<p><b>Rare</b> (0.01% to 0.1%): Exacerbation/precipitation of psoriasis, erythema multiforme, toxic epidermal necrolysis, Stevens-Johnson syndrome</p>
<p><b>Very rare</b> (less than 0.01%): Exfoliative dermatitis, similar desquamation-type events</p>
<p><b>Frequency not reported</b>: Macular/urticarial/purpuric skin eruptions, lichenoid keratosis, acute generalized exanthematous pustulosis, depigmentation, rashes</p>
<p><b>Postmarketing reports</b>: Erythema multiforme, Stevens-Johnson syndrome, toxic epidermal necrolysis, exfoliative dermatitis, pleomorphic skin eruptions, lichen planus-like eruptions, hair loss, skin/mucosal pigmentary changes, pruritus, drug reaction with eosinophilia and systemic symptoms (DRESS) syndrome, bleaching of hair pigment, photosensitivity reaction<sup>[Ref]</sup></p><h3>Gastrointestinal</h3><p><b>Very common</b> (10% or more): Gastrointestinal disturbances (e.g., nausea, vomiting, diarrhea)</p>
<p><b>Frequency not reported</b>: Gastrointestinal disorder, abdominal pain</p>
<p><b>Postmarketing reports</b>: Nausea, vomiting, diarrhea, abdominal cramps<sup>[Ref]</sup></p><h3>Nervous system</h3><p><b>Very common</b> (10% or more): Headache</p>
<p><b>Uncommon</b> (0.1% to 1%): Neuropathy, ototoxicity (e.g., tinnitus, hypoacusis, deafness neurosensory/nerve deafness)</p>
<p><b>Rare</b> (0.01% to 0.1%): Convulsions, polyneuropathy</p>
<p><b>Frequency not reported</b>: Visual field defects, neuromyopathy, convulsive seizures, polyneuritis, dizziness, nonconvulsive status epilepticus/seizures, development of extrapyramidal rigidity</p>
<p><b>Postmarketing reports</b>: Convulsions, mild headache (transient), polyneuropathy, acute extrapyramidal disorders (e.g., dystonia, dyskinesia, tongue protrusion, torticollis), sensorimotor disorders, depression of tendon reflexes, abnormal nerve conduction, nerve type deafness, tinnitus, reduced hearing (in patients with preexisting auditory damage)<sup>[Ref]</sup></p><h3>Psychiatric</h3><p>Mania has been reported in a patient taking this drug for malarial prophylaxis.  These symptoms resolved after discontinuation and recurred with rechallenge.<sup>[Ref]</sup></p><p><b>Very common</b> (10% or more): Insomnia</p>
<p><b>Common</b> (1% to 10%): Depression</p>
<p><b>Rare</b> (0.01% to 0.1%): Hallucinations, psychiatric disorders (e.g., anxiety, agitation, confusion, hallucinations, delirium)</p>
<p><b>Frequency not reported</b>: Mania, other psychiatric and neurologic disturbances, paranoia</p>
<p><b>Postmarketing reports</b>: Neuropsychiatric changes, psychotic disorder/psychosis, delirium, anxiety, agitation, insomnia, confusion, hallucinations, personality changes, depression, suicidal behavior<sup>[Ref]</sup></p><h3>Hypersensitivity</h3><p><b>Common</b> (1% to 10%): Hypersensitivity/allergic reaction (including urticaria, angioedema, vasculitis), anaphylactic reactions</p>
<p><b>Frequency not reported</b>: Anaphylactoid reaction</p>
<p><b>Postmarketing reports</b>: Anaphylactic reaction (including angioedema)</p><h3>Cardiovascular</h3><p><b>Uncommon</b> (0.1% to 1%): Cardiomyopathy</p>
<p><b>Rare</b> (0.01% to 0.1%): Cardiac arrhythmias (including QT prolongation, torsade de pointes, ventricular tachycardia, ventricular fibrillation)</p>
<p><b>Frequency not reported</b>: Atrioventricular block, cardiac hypertrophy, restrictive cardiomyopathy, congestive heart failure, complete heart block</p>
<p><b>Postmarketing reports</b>: Hypotension, ECG changes (particularly inversion/depression of T-wave with widening of QRS complex), cardiomyopathy (sometimes resulting in cardiac failure; some with fatal outcome), cardiac arrhythmias, conduction disorders (e.g., bundle branch block/atrioventricular block), QT interval prolongation, torsade de pointes, ventricular tachycardia, ventricular fibrillation<sup>[Ref]</sup></p><p>Cardiomyopathy has been reported during long-term therapy at high doses.</p>
<p></p>
<p>Cardiac arrhythmias (including QT prolongation, torsade de pointes, ventricular tachycardia, and ventricular fibrillation) have been reported with therapeutic doses as well as with overdose; the risk was greater when high doses were administered.  Fatal cases have been reported.</p>
<p></p>
<p>ECG changes have been reported at high doses.  ECG changes observed included prolongation of the QRS interval and, rarely, complete heart block.  Biopsies of cardiac tissue characteristically showed no inflammatory infiltrates, severe vacuolation, and myocytes containing myeloid bodies and lysosomes.</p>
<p></p>
<p>Conduction disorders (e.g., bundle branch block/atrioventricular block) have been reported with therapeutic doses as well as with overdose.<sup>[Ref]</sup></p><h3>Musculoskeletal</h3><p><b>Uncommon</b> (0.1% to 1%): Myopathy</p>
<p><b>Frequency not reported</b>: Myasthenia-like syndromes</p>
<p><b>Postmarketing reports</b>: Skeletal muscle myopathy/neuromyopathy (leading to progressive weakness, atrophy of proximal muscle groups)<sup>[Ref]</sup></p><h3>Hematologic</h3><p><b>Rare</b> (0.01% to 0.1%): Bone marrow failure/depression (including aplastic anemia, agranulocytosis, pancytopenia, thrombocytopenia, neutropenia)</p>
<p><b>Postmarketing reports</b>: Pancytopenia, aplastic anemia, reversible agranulocytosis, thrombocytopenia, neutropenia, hemolytic anemia (in glucose-6-phosphate dehydrogenase deficient patients)<sup>[Ref]</sup></p><h3>Hepatic</h3><p><b>Rare</b> (0.01% to 0.1%): Changes in liver function (including hepatitis, abnormal liver function tests)</p>
<p><b>Frequency not reported</b>: Hepatotoxicity (in a patient with porphyria cutanea tarda)</p>
<p><b>Postmarketing reports</b>: Hepatitis, elevated liver enzymes<sup>[Ref]</sup></p><h3>Metabolic</h3><p><b>Frequency not reported</b>: Hypokalemia (associated with acute ingestion)</p>
<p><b>Postmarketing reports</b>: Anorexia, hypoglycemia<sup>[Ref]</sup></p><p>The usefulness of hypokalemia as an indicator in the evaluation of chloroquine toxicity was studied in a retrospective series of 191 acute chloroquine poisonings.  Results indicated that the risk of severe poisoning and death were proportional to the degree of hypokalemia.<sup>[Ref]</sup></p><h3>Respiratory</h3><p><b>Frequency not reported</b>: Diffuse parenchymal lung disease<sup>[Ref]</sup></p><div class="referenceList"><h4 id="refs">References</h4><p id="ref_1">1. Ehrenfeld M, Nesher R, Merin S "Delayed-onset chloroquine retinopathy." Br J Ophthalmol 70 (1986): 281-3</p><p id="ref_2">2. Freedman DO "Clinical practice. Malaria prevention in short-term travelers." N Engl J Med 359 (2008): 603-12</p><p id="ref_3">3. Thorogood N,  Atwal S,  Mills W, et al. "The risk of antimalarials in patients with renal failure." Postgrad Med J 83 (2007): e8</p><p id="ref_4">4. Frisk-Holmberg M, Bergkvist Y, Domeij-Nyberg B, et al "Chloroquine serum concentration and side effects: evidence for dose-dependent kinetics." Clin Pharmacol Ther 25 (1979): 345-50</p><p id="ref_5">5. Tonnesmann E,  Stroehmann I,  Kandolf R, et al. "Cardiomyopathy caused by longterm treatment with chloroquine: a rare disease, or  a rare diagnosis?" J Rheumatol 39 (2012): 1099-103</p><p id="ref_6">6. Craig GL, Buchanan WW "Antirheumatic drugs: clinical pharmacology and therapeutic use." Drugs 20 (1980): 453-84</p><p id="ref_7">7. Puavilai S, Kunavisarut S, Vatanasuk M, Timpatanapong P, Sriwong ST, Janwitayanujit S, Nantiruj K, Totemchokchyakarn K, Ruangkanchana "Ocular toxicity of chloroquine among Thai patients." Int J Dermatol 38 (1999): 934-7</p><p id="ref_8">8. Sassani JW, Brucker AJ, Cobbs W, Campbell C "Progressive chloroquine retinopathy." Ann Ophthalmol 15 (1983): 19-22</p><p id="ref_9">9. Goldstein JH "Effects of drugs on cornea, conjunctiva, and lids." Int Ophthalmol Clin 11 (1971): 13-34</p><p id="ref_10">10. Schlagenhauf P,  Tschopp A,  Johnson R, et al. "Tolerability of malaria chemoprophylaxis in non-immune travellers to sub-Saharan Africa: multicentre, randomised, double blind, four arm study." BMJ 327 (2003): 1078</p><p id="ref_11">11. Okor RS "Onset of pruritogenicity of chloroquine and the implication for the timing of suppressive therapy." J Clin Pharm Ther 16 (1991): 463-5</p><p id="ref_12">12. Olatunde IA "Chloroquine concentrations in the skin of rabbits and man." Br J Clin Pharmacol 43 (1971): 335-40</p><p id="ref_13">13. Rustogi A,  Munshi A,  Jalali R "Unexpected skin reaction induced by radiotherapy after chloroquine use." Lancet Oncol 7 (2006): 608-9</p><p id="ref_14">14. Spencer HC, Poulter NR, Lury JD, Poulter CJ "Chloroquine-associated pruritus in a European." Br Med J 285 (1982): 1703-4</p><p id="ref_15">15. Janier M, Froidevaux D, LonsDanic D, Daniel F "Acute generalized exanthematous pustulosis due to the combination of chloroquine and proguanil." Dermatology 196 (1998): 271</p><p id="ref_16">16. Mallett R "Risks and benefits of prophylactic antimalarial drugs." Br Med J 299 (1989): 1400</p><p id="ref_17">17. Boffa MJ, Chalmers RJG "Toxic epidermal necrolysis due to chloroquine phosphate." Br J Dermatol 131 (1994): 444-5</p><p id="ref_18">18. Ajayi AA, Akinleye AO, Udoh SJ, et al "The effects of prednisolone and niacin on chloroquine-induced pruritis in malaria." Eur J Clin Pharmacol 41 (1991): 383-5</p><p id="ref_19">19. Ezeamuzie IC,  Igbigbi PS,  Ambakederemo AW,  Abila B,  Nwaejike IN "Halofantrine-induced pruritus amongst subjects who itch to chloroquine." J Trop Med Hyg 94 (1991): 184-8</p><p id="ref_20">20. Wilairatana P, Looareesuwan S, Riganti M, TejaIsavadharm P, Keeratithakul D, Eickmeyer S, Walsh DS "Pustular eruption in a malaria patient treated with chloroquine." Int J Dermatol 37 (1998): 713-4</p><p id="ref_21">21. Levy H "Chloroquine-induced pigmentation." S Afr Med J 62 (1982): 735-7</p><p id="ref_22">22. Donovan JC,  Price VH "Images in clinical medicine. Chloroquine-induced hair hypopigmentation." N Engl J Med 363 (2010): 372</p><p id="ref_23">23. Van Weelden HV, Bolling HH, De La Faille HB, et al "Photosensitivity caused by chloroquine." Arch Dermatol 118 (1982): 290</p><p id="ref_24">24. Olsen TG "Chloroquine and psoriasis." Ann Intern Med 94 (1981): 546-7</p><p id="ref_25">25. Martin-Garcia RF,  Camacho Ndel R,  Sanchez JL "Chloroquine-induced, vitiligo-like depigmentation." J Am Acad Dermatol 48 (2003): 981-3</p><p id="ref_26">26. Selvaag E "Chloroquine-induced vitiligo - a case report and review of the literature." Acta Derm Venereol 76 (1996): 166-7</p><p id="ref_27">27. Vestey JP, Savin JA "Psoriasis worsened by antimalarial prophylaxis." J Infect 24 (1992): 211-2</p><p id="ref_28">28. Bakshi R,  Hermeling-Fritz I,  Gathmann I,  Alteri E "An integrated assessment of the clinical safety of artemether-lumefantrine: a new oral fixed-dose combination antimalarial drug." Trans R Soc Trop Med Hyg 94 (2000): 419-24</p><p id="ref_29">29. Liu AC "Hepatotoxic reaction to chloroquine phosphate in a patient with previously unrecognized porphyria cutanea tarda." West J Med 162 (1995): 548-51</p><p id="ref_30">30. Genovese MC,  Becker JC,  Schiff M, et al. "Abatacept for rheumatoid arthritis refractory to tumor necrosis factor alpha inhibition." N Engl J Med 353 (2005): 1114-23</p><p id="ref_31">31. Bhasin DK, Chhina RS, Sachdeva JR "Endoscopic assessment of chloroquine phosphate-induced damage to esophageal, gastric, and duodenal mucosa." Am J Gastroenterol 86 (1991): 434-7</p><p id="ref_32">32. Benbadis SR, Vanness PC "Chloroquine and nonconvulsive status epilepticus." Ann Intern Med 124 (1996): 614</p><p id="ref_33">33. "Product Information. Aralen (chloroquine)." Sanofi Winthrop Pharmaceuticals, New York, NY. </p><p id="ref_34">34. Mulhauser P, Allemann Y "Chloroquine and nonconvulsive status epilepticus." Ann Intern Med 123 (1995): 76-7</p><p id="ref_35">35. Lovestone S "Chloroquine-induced mania." Br J Psychiatry 159 (1991): 164-5</p><p id="ref_36">36. Akhtar S, Mukherjee S "Chloroquine induced mania." Int J Psychiatry Med 23 (1993): 349-56</p><p id="ref_37">37. Singh RP, Sinha AK "Neuropsychiatric toxicity of chlorquine." J Indian Med Assoc 77 (1981): 133-4</p><p id="ref_38">38. Mohan D, Mohandas E, Rajat R "Chloroquine psychosis: a chemical psychosis?" J Natl Med Assoc 73 (1981): 1073-6</p><p id="ref_39">39. Cooper RG "Chloroquine should be used with care in mental health disorders." Indian J Physiol Pharmacol 52 (2008): 97-8</p><p id="ref_40">40. Telgt DS,  van der Ven AJ,  Schimmer B,  Droogleever-Fortuyn HA,  Sauerwein RW "Serious psychiatric symptoms after chloroquine treatment following experimental malaria infection." Ann Pharmacother 39 (2005): 551-4</p><p id="ref_41">41. Costedoat-Chalumeau N,  Hulot JS,  Amoura Z, et al. "Cardiomyopathy Related to Antimalarial Therapy with Illustrative Case Report." Cardiology 107 (2006): 73-80</p><p id="ref_42">42. Looareesuwan S, White NJ, Chanthavanich P, et al "Cardiovascular toxicity and distribution kinetics of intravenous chloroquine." Br J Clin Pharmacol 22 (1986): 31-6</p><p id="ref_43">43. Ratliff NB, Este ML, Myles JL, et al "Diagnosis of chloroquine cardiomyopathy by endomyocardial biopsy." N Engl J Med 316 (1987): 191-3</p><p id="ref_44">44. Veinot JP, Mai KT, Zarychanski R "Chloroquine related cardiac toxicity." J Rheumatol 25 (1998): 1221-5</p><p id="ref_45">45. ReussBorst M, Berner B, Wulf G, Muller GA "Complete heart block as a rare complication of treatment with chloroquine." J Rheumatol 26 (1999): 1394-5</p><p id="ref_46">46. McAllister HA Jr, Ferrans VJ, Hall RJ et al "Cholorquine-induced cardiomyopathy." Arch Pathol Lab Med 111 (1987): 953-6</p><p id="ref_47">47. Baguet JP, Tremel F, Fabre M "Chloroquine cardiomyopathy with conduction disorders." Heart 81 (1999): 221-3</p><p id="ref_48">48. Iglesias Cubero G, Rodriguez Reguero JJ, Rojo Ortega JM "Restrictive cardiomyopathy caused by chloroquine." Br Heart J 69 (1993): 451-2</p><p id="ref_49">49. Robberecht W, Bednarik J, Bourgeois P, et al "Myasthenic syndrome caused by direct effect of chloroquine on neuromuscular junction." Arch Neurol 46 (1989): 464-8</p><p id="ref_50">50. Parodi A, Regesta G, Rebora A "Chloroquine-induced neuromyopathy." Dermatologica 171 (1985): 203-5</p><p id="ref_51">51. Nucci A, Queiroz LS, Samara AM "Chloroquine neuromyopathy." Clin Neuropathol 15 (1996): 256-8</p><p id="ref_52">52. Avinazubieta JA, Johnson ES, Suarezalmazor ME, Russell AS "Incidence of myopathy in patients treated with antimalarials. a report of three cases and a review of the literature." Br J Rheumatol 34 (1995): 166-70</p><p id="ref_53">53. Estes ML, Wing-Wilson D, Chou SM, et al "Chloroquine neuromyotoxicity." Am J Med 82 (1987): 447-55</p><p id="ref_54">54. Wasay M, Wolfe GI, Herrold JM, Burns DK, Barohn RJ "Chloroquine myopathy and neuropathy with elevated CSF protein." Neurology 51 (1998): 1226-7</p><p id="ref_55">55. Schirlanzoni A, Mantegazza R, Mora M, et al "Chloroquine myopathy and myasthenia-like syndrome." Muscle Nerve 11 (1988): 114-9</p><p id="ref_56">56. Hearn J, Tiliakos NA "Myasthenia gravis caused by pencillamine and chloroquine therapy for rheumatoid arthritis." South Med J 79 (1986): 1185-6</p><p id="ref_57">57. Winkelman RK, Merwin CF, Brunsting LA "Antimalarial therapy of lupus erythematosus." Ann Intern Med 55 (1961): 772-6</p><p id="ref_58">58. Polano MK, Cats A, van Olden GAJ "Agranulocytosis following treatment with hydroxychloroquine sulphate." Lancet 1 (1965): 1275</p><p id="ref_59">59. Buchanan N "Hypokalaemia and acute chloroquine ingestion." Lancet 347 (1996): 404</p><p id="ref_60">60. Clemessy JL, Borron SW, Baud FJ "Hypokalaemia and acute chloroquine ingestion - reply." Lancet 347 (1996): 404-5</p><p id="ref_61">61. Angel G, Berthelot PG, Rogier C "Hypokalaemia related to acute chloroquine poisoning." Lancet 346 (1995): 1625</p></div>
<h2 class="ddc-anchor-offset" id="faq">Frequently asked questions</h2>
<ul>
<li>An Update: Is hydroxychloroquine effective for COVID-19?</li>
</ul>
<div class="more-resources" id="moreResources">
<h2>More about Aralen (chloroquine)</h2>
<ul class="more-resources-list more-resources-list-general">
<li>During Pregnancy or 
Breastfeeding</li>
<li>Dosage Information</li>
<li>Drug Interactions</li>
<li>Drug class: amebicides</li>
<li>FDA Alerts (2)</li>
</ul>
<h3>Consumer resources</h3>
<dl class="more-resources-other-brands more-resources-other-brands-consumer"><dt>Other brands</dt><dd>Aralen Phosphate</dd></dl>
<h3>Professional resources</h3>
<ul class="more-resources-list more-resources-list-professional">
<li>Prescribing Information</li>
<li data-more-config-id="list-data-resources-professional">... +1 more</li>
</ul>
<h3>Related treatment guides</h3>
<ul class="more-resources-list more-resources-list-conditions">
<li>Amebiasis</li>
<li>Malaria</li>
<li>Malaria Prevention</li>
<li>Sarcoidosis</li>
</ul>
</div>
<h2>Further information</h2><p class="ddc-disclaimer">Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.</p>
<p>Some side effects may not be reported. You may report them to the FDA.</p>
<p class="ddc-disclaimer-link">Medical Disclaimer</p>
<script>
function showRefs(refs) {
	if (!document.querySelectorAll) {
		return;
	}

	var referenceIds = refs ? refs.split(',') : [];
	var referenceTitle = referenceIds.length
		 ? "References relevant to chosen section <span class='ddc-text-size-small font-weight-normal'>(<a href='#refs' onclick='showRefs(\"\"); return false;'>Show all references</a>)</span>"
		 : "References";
	document.getElementById('refs').innerHTML = referenceTitle;

	// Show/hide reference items
	var referenceList = document.querySelectorAll('.referenceList p');
	referenceList.forEach(function(item) {
		var id = item.id.replace('ref_', '');
		if (!referenceIds.length || referenceIds.includes(id)) {
			item.style.display = 'block';
		}
		else {
			item.style.display = 'none';
		}
	});
}
</script>
</p><h2 class="ddc-anchor-offset" id="professional">For Healthcare Professionals</h2><p><i>Applies to chloroquine: compounding powder, injectable solution, oral tablet</i></p><h3>Ocular</h3><p>Retinopathy and irreversible retinal damage have been reported during long-term, high-dose therapy.</p><p></p><p>Maculopathy and macular degeneration have been reported and may be irreversible.</p><p></p><p>Irreversible retinopathy with retinal pigmentation changes (bull's eye appearance) and visual field defects (paracentral scotomas) have been reported in patients receiving long-term or high-dose 4-aminoquinoline therapy.<sup>[Ref]</sup></p><p><b>Common</b> (1% to 10%): Transient blurred vision</p><p><b>Rare</b> (0.01% to 0.1%): Reversible corneal opacity, retinopathy, irreversible retinal damage</p><p><b>Frequency not reported</b>: Retinal degeneration, macular defects of color vision, pigmentation, optic atrophy, scotomas, blindness, corneal opacity, pigmented deposits, vision blurred/difficulty focusing, accommodation disorder, diplopia, field defects, double vision, decreased visual acuity, color-vision defects, pigmentary retinopathy, corneal deposits, keratopathy, decreased corneal sensitivity, corneal edema</p><p><b>Postmarketing reports</b>: Maculopathy, macular degeneration, visual disturbances (blurred vision, focusing/accommodation difficulty), nyctalopia, scotomatous vision with field defects of paracentral/pericentral ring types/typically temporal scotomas (e.g., difficulty in reading with words tending to disappear, seeing half an object, misty vision, fog before the eyes), reversible corneal opacities</p><p></p><p>4-aminoquinoline therapy:</p><p>-Postmarketing reports: Irreversible retinopathy with retinal pigmentation changes (bull's eye appearance), visual field defects (paracentral scotomas)<sup>[Ref]</sup></p><h3>Dermatologic</h3><p>Pruritus has been seen more commonly in Africans.  The onset was generally 6 to 48 hours after the first dose and antihistamines did not always control the pruritus.</p><p></p><p>Pigmentation disorder (including bluish-black pigmentation of the nails and mucosa) has been reported with long-term use.  Increased pigmentation of the skin and mucous membranes was generally of a bluish color was not always reversible on discontinuation.</p><p></p><p>Several cases of hypopigmentation of the skin have been reported.  Most of the patients described were African or of African descent with dark skin who had been exposed to the sun.  One was a Hispanic patient who developed vitiligo-like skin depigmentation after 1 month of therapy for cutaneous lupus erythematosus.  The skin rapidly repigmented after this drug was discontinued.</p><p></p><p>At least 2 cases of exacerbation of psoriasis requiring hospitalization have been reported.<sup>[Ref]</sup></p><p><b>Very common</b> (10% or more): Pruritus</p><p><b>Common</b> (1% to 10%): Skin eruptions, urticaria</p><p><b>Uncommon</b> (0.1% to 1%): Alopecia, pigmentation disorder (including bluish-black pigmentation of the nails and mucosa)</p><p><b>Rare</b> (0.01% to 0.1%): Exacerbation/precipitation of psoriasis, erythema multiforme, toxic epidermal necrolysis, Stevens-Johnson syndrome</p><p><b>Very rare</b> (less than 0.01%): Exfoliative dermatitis, similar desquamation-type events</p><p><b>Frequency not reported</b>: Macular/urticarial/purpuric skin eruptions, lichenoid keratosis, acute generalized exanthematous pustulosis, depigmentation, rashes</p><p><b>Postmarketing reports</b>: Erythema multiforme, Stevens-Johnson syndrome, toxic epidermal necrolysis, exfoliative dermatitis, pleomorphic skin eruptions, lichen planus-like eruptions, hair loss, skin/mucosal pigmentary changes, pruritus, drug reaction with eosinophilia and systemic symptoms (DRESS) syndrome, bleaching of hair pigment, photosensitivity reaction<sup>[Ref]</sup></p><h3>Gastrointestinal</h3><p><b>Very common</b> (10% or more): Gastrointestinal disturbances (e.g., nausea, vomiting, diarrhea)</p><p><b>Frequency not reported</b>: Gastrointestinal disorder, abdominal pain</p><p><b>Postmarketing reports</b>: Nausea, vomiting, diarrhea, abdominal cramps<sup>[Ref]</sup></p><h3>Nervous system</h3><p><b>Very common</b> (10% or more): Headache</p><p><b>Uncommon</b> (0.1% to 1%): Neuropathy, ototoxicity (e.g., tinnitus, hypoacusis, deafness neurosensory/nerve deafness)</p><p><b>Rare</b> (0.01% to 0.1%): Convulsions, polyneuropathy</p><p><b>Frequency not reported</b>: Visual field defects, neuromyopathy, convulsive seizures, polyneuritis, dizziness, nonconvulsive status epilepticus/seizures, development of extrapyramidal rigidity</p><p><b>Postmarketing reports</b>: Convulsions, mild headache (transient), polyneuropathy, acute extrapyramidal disorders (e.g., dystonia, dyskinesia, tongue protrusion, torticollis), sensorimotor disorders, depression of tendon reflexes, abnormal nerve conduction, nerve type deafness, tinnitus, reduced hearing (in patients with preexisting auditory damage)<sup>[Ref]</sup></p><h3>Psychiatric</h3><p>Mania has been reported in a patient taking this drug for malarial prophylaxis.  These symptoms resolved after discontinuation and recurred with rechallenge.<sup>[Ref]</sup></p><p><b>Very common</b> (10% or more): Insomnia</p><p><b>Common</b> (1% to 10%): Depression</p><p><b>Rare</b> (0.01% to 0.1%): Hallucinations, psychiatric disorders (e.g., anxiety, agitation, confusion, hallucinations, delirium)</p><p><b>Frequency not reported</b>: Mania, other psychiatric and neurologic disturbances, paranoia</p><p><b>Postmarketing reports</b>: Neuropsychiatric changes, psychotic disorder/psychosis, delirium, anxiety, agitation, insomnia, confusion, hallucinations, personality changes, depression, suicidal behavior<sup>[Ref]</sup></p><h3>Hypersensitivity</h3><p><b>Common</b> (1% to 10%): Hypersensitivity/allergic reaction (including urticaria, angioedema, vasculitis), anaphylactic reactions</p><p><b>Frequency not reported</b>: Anaphylactoid reaction</p><p><b>Postmarketing reports</b>: Anaphylactic reaction (including angioedema)</p><h3>Cardiovascular</h3><p><b>Uncommon</b> (0.1% to 1%): Cardiomyopathy</p><p><b>Rare</b> (0.01% to 0.1%): Cardiac arrhythmias (including QT prolongation, torsade de pointes, ventricular tachycardia, ventricular fibrillation)</p><p><b>Frequency not reported</b>: Atrioventricular block, cardiac hypertrophy, restrictive cardiomyopathy, congestive heart failure, complete heart block</p><p><b>Postmarketing reports</b>: Hypotension, ECG changes (particularly inversion/depression of T-wave with widening of QRS complex), cardiomyopathy (sometimes resulting in cardiac failure; some with fatal outcome), cardiac arrhythmias, conduction disorders (e.g., bundle branch block/atrioventricular block), QT interval prolongation, torsade de pointes, ventricular tachycardia, ventricular fibrillation<sup>[Ref]</sup></p><p>Cardiomyopathy has been reported during long-term therapy at high doses.</p><p></p><p>Cardiac arrhythmias (including QT prolongation, torsade de pointes, ventricular tachycardia, and ventricular fibrillation) have been reported with therapeutic doses as well as with overdose; the risk was greater when high doses were administered.  Fatal cases have been reported.</p><p></p><p>ECG changes have been reported at high doses.  ECG changes observed included prolongation of the QRS interval and, rarely, complete heart block.  Biopsies of cardiac tissue characteristically showed no inflammatory infiltrates, severe vacuolation, and myocytes containing myeloid bodies and lysosomes.</p><p></p><p>Conduction disorders (e.g., bundle branch block/atrioventricular block) have been reported with therapeutic doses as well as with overdose.<sup>[Ref]</sup></p><h3>Musculoskeletal</h3><p><b>Uncommon</b> (0.1% to 1%): Myopathy</p><p><b>Frequency not reported</b>: Myasthenia-like syndromes</p><p><b>Postmarketing reports</b>: Skeletal muscle myopathy/neuromyopathy (leading to progressive weakness, atrophy of proximal muscle groups)<sup>[Ref]</sup></p><h3>Hematologic</h3><p><b>Rare</b> (0.01% to 0.1%): Bone marrow failure/depression (including aplastic anemia, agranulocytosis, pancytopenia, thrombocytopenia, neutropenia)</p><p><b>Postmarketing reports</b>: Pancytopenia, aplastic anemia, reversible agranulocytosis, thrombocytopenia, neutropenia, hemolytic anemia (in glucose-6-phosphate dehydrogenase deficient patients)<sup>[Ref]</sup></p><h3>Hepatic</h3><p><b>Rare</b> (0.01% to 0.1%): Changes in liver function (including hepatitis, abnormal liver function tests)</p><p><b>Frequency not reported</b>: Hepatotoxicity (in a patient with porphyria cutanea tarda)</p><p><b>Postmarketing reports</b>: Hepatitis, elevated liver enzymes<sup>[Ref]</sup></p><h3>Metabolic</h3><p><b>Frequency not reported</b>: Hypokalemia (associated with acute ingestion)</p><p><b>Postmarketing reports</b>: Anorexia, hypoglycemia<sup>[Ref]</sup></p><p>The usefulness of hypokalemia as an indicator in the evaluation of chloroquine toxicity was studied in a retrospective series of 191 acute chloroquine poisonings.  Results indicated that the risk of severe poisoning and death were proportional to the degree of hypokalemia.<sup>[Ref]</sup></p><h3>Respiratory</h3><p><b>Frequency not reported</b>: Diffuse parenchymal lung disease<sup>[Ref]</sup></p><p id="ref_1">1. Ehrenfeld M, Nesher R, Merin S "Delayed-onset chloroquine retinopathy." Br J Ophthalmol 70 (1986): 281-3</p><p id="ref_2">2. Freedman DO "Clinical practice. Malaria prevention in short-term travelers." N Engl J Med 359 (2008): 603-12</p><p id="ref_3">3. Thorogood N,  Atwal S,  Mills W, et al. "The risk of antimalarials in patients with renal failure." Postgrad Med J 83 (2007): e8</p><p id="ref_4">4. Frisk-Holmberg M, Bergkvist Y, Domeij-Nyberg B, et al "Chloroquine serum concentration and side effects: evidence for dose-dependent kinetics." Clin Pharmacol Ther 25 (1979): 345-50</p><p id="ref_5">5. Tonnesmann E,  Stroehmann I,  Kandolf R, et al. "Cardiomyopathy caused by longterm treatment with chloroquine: a rare disease, or  a rare diagnosis?" J Rheumatol 39 (2012): 1099-103</p><p id="ref_6">6. Craig GL, Buchanan WW "Antirheumatic drugs: clinical pharmacology and therapeutic use." Drugs 20 (1980): 453-84</p><p id="ref_7">7. Puavilai S, Kunavisarut S, Vatanasuk M, Timpatanapong P, Sriwong ST, Janwitayanujit S, Nantiruj K, Totemchokchyakarn K, Ruangkanchana "Ocular toxicity of chloroquine among Thai patients." Int J Dermatol 38 (1999): 934-7</p><p id="ref_8">8. Sassani JW, Brucker AJ, Cobbs W, Campbell C "Progressive chloroquine retinopathy." Ann Ophthalmol 15 (1983): 19-22</p><p id="ref_9">9. Goldstein JH "Effects of drugs on cornea, conjunctiva, and lids." Int Ophthalmol Clin 11 (1971): 13-34</p><p id="ref_10">10. Schlagenhauf P,  Tschopp A,  Johnson R, et al. "Tolerability of malaria chemoprophylaxis in non-immune travellers to sub-Saharan Africa: multicentre, randomised, double blind, four arm study." BMJ 327 (2003): 1078</p><p id="ref_11">11. Okor RS "Onset of pruritogenicity of chloroquine and the implication for the timing of suppressive therapy." J Clin Pharm Ther 16 (1991): 463-5</p><p id="ref_12">12. Olatunde IA "Chloroquine concentrations in the skin of rabbits and man." Br J Clin Pharmacol 43 (1971): 335-40</p><p id="ref_13">13. Rustogi A,  Munshi A,  Jalali R "Unexpected skin reaction induced by radiotherapy after chloroquine use." Lancet Oncol 7 (2006): 608-9</p><p id="ref_14">14. Spencer HC, Poulter NR, Lury JD, Poulter CJ "Chloroquine-associated pruritus in a European." Br Med J 285 (1982): 1703-4</p><p id="ref_15">15. Janier M, Froidevaux D, LonsDanic D, Daniel F "Acute generalized exanthematous pustulosis due to the combination of chloroquine and proguanil." Dermatology 196 (1998): 271</p><p id="ref_16">16. Mallett R "Risks and benefits of prophylactic antimalarial drugs." Br Med J 299 (1989): 1400</p><p id="ref_17">17. Boffa MJ, Chalmers RJG "Toxic epidermal necrolysis due to chloroquine phosphate." Br J Dermatol 131 (1994): 444-5</p><p id="ref_18">18. Ajayi AA, Akinleye AO, Udoh SJ, et al "The effects of prednisolone and niacin on chloroquine-induced pruritis in malaria." Eur J Clin Pharmacol 41 (1991): 383-5</p><p id="ref_19">19. Ezeamuzie IC,  Igbigbi PS,  Ambakederemo AW,  Abila B,  Nwaejike IN "Halofantrine-induced pruritus amongst subjects who itch to chloroquine." J Trop Med Hyg 94 (1991): 184-8</p><p id="ref_20">20. Wilairatana P, Looareesuwan S, Riganti M, TejaIsavadharm P, Keeratithakul D, Eickmeyer S, Walsh DS "Pustular eruption in a malaria patient treated with chloroquine." Int J Dermatol 37 (1998): 713-4</p><p id="ref_21">21. Levy H "Chloroquine-induced pigmentation." S Afr Med J 62 (1982): 735-7</p><p id="ref_22">22. Donovan JC,  Price VH "Images in clinical medicine. Chloroquine-induced hair hypopigmentation." N Engl J Med 363 (2010): 372</p><p id="ref_23">23. Van Weelden HV, Bolling HH, De La Faille HB, et al "Photosensitivity caused by chloroquine." Arch Dermatol 118 (1982): 290</p><p id="ref_24">24. Olsen TG "Chloroquine and psoriasis." Ann Intern Med 94 (1981): 546-7</p><p id="ref_25">25. Martin-Garcia RF,  Camacho Ndel R,  Sanchez JL "Chloroquine-induced, vitiligo-like depigmentation." J Am Acad Dermatol 48 (2003): 981-3</p><p id="ref_26">26. Selvaag E "Chloroquine-induced vitiligo - a case report and review of the literature." Acta Derm Venereol 76 (1996): 166-7</p><p id="ref_27">27. Vestey JP, Savin JA "Psoriasis worsened by antimalarial prophylaxis." J Infect 24 (1992): 211-2</p><p id="ref_28">28. Bakshi R,  Hermeling-Fritz I,  Gathmann I,  Alteri E "An integrated assessment of the clinical safety of artemether-lumefantrine: a new oral fixed-dose combination antimalarial drug." Trans R Soc Trop Med Hyg 94 (2000): 419-24</p><p id="ref_29">29. Liu AC "Hepatotoxic reaction to chloroquine phosphate in a patient with previously unrecognized porphyria cutanea tarda." West J Med 162 (1995): 548-51</p><p id="ref_30">30. Genovese MC,  Becker JC,  Schiff M, et al. "Abatacept for rheumatoid arthritis refractory to tumor necrosis factor alpha inhibition." N Engl J Med 353 (2005): 1114-23</p><p id="ref_31">31. Bhasin DK, Chhina RS, Sachdeva JR "Endoscopic assessment of chloroquine phosphate-induced damage to esophageal, gastric, and duodenal mucosa." Am J Gastroenterol 86 (1991): 434-7</p><p id="ref_32">32. Benbadis SR, Vanness PC "Chloroquine and nonconvulsive status epilepticus." Ann Intern Med 124 (1996): 614</p><p id="ref_33">33. "Product Information. Aralen (chloroquine)." Sanofi Winthrop Pharmaceuticals, New York, NY. </p><p id="ref_34">34. Mulhauser P, Allemann Y "Chloroquine and nonconvulsive status epilepticus." Ann Intern Med 123 (1995): 76-7</p><p id="ref_35">35. Lovestone S "Chloroquine-induced mania." Br J Psychiatry 159 (1991): 164-5</p><p id="ref_36">36. Akhtar S, Mukherjee S "Chloroquine induced mania." Int J Psychiatry Med 23 (1993): 349-56</p><p id="ref_37">37. Singh RP, Sinha AK "Neuropsychiatric toxicity of chlorquine." J Indian Med Assoc 77 (1981): 133-4</p><p id="ref_38">38. Mohan D, Mohandas E, Rajat R "Chloroquine psychosis: a chemical psychosis?" J Natl Med Assoc 73 (1981): 1073-6</p><p id="ref_39">39. Cooper RG "Chloroquine should be used with care in mental health disorders." Indian J Physiol Pharmacol 52 (2008): 97-8</p><p id="ref_40">40. Telgt DS,  van der Ven AJ,  Schimmer B,  Droogleever-Fortuyn HA,  Sauerwein RW "Serious psychiatric symptoms after chloroquine treatment following experimental malaria infection." Ann Pharmacother 39 (2005): 551-4</p><p id="ref_41">41. Costedoat-Chalumeau N,  Hulot JS,  Amoura Z, et al. "Cardiomyopathy Related to Antimalarial Therapy with Illustrative Case Report." Cardiology 107 (2006): 73-80</p><p id="ref_42">42. Looareesuwan S, White NJ, Chanthavanich P, et al "Cardiovascular toxicity and distribution kinetics of intravenous chloroquine." Br J Clin Pharmacol 22 (1986): 31-6</p><p id="ref_43">43. Ratliff NB, Este ML, Myles JL, et al "Diagnosis of chloroquine cardiomyopathy by endomyocardial biopsy." N Engl J Med 316 (1987): 191-3</p><p id="ref_44">44. Veinot JP, Mai KT, Zarychanski R "Chloroquine related cardiac toxicity." J Rheumatol 25 (1998): 1221-5</p><p id="ref_45">45. ReussBorst M, Berner B, Wulf G, Muller GA "Complete heart block as a rare complication of treatment with chloroquine." J Rheumatol 26 (1999): 1394-5</p><p id="ref_46">46. McAllister HA Jr, Ferrans VJ, Hall RJ et al "Cholorquine-induced cardiomyopathy." Arch Pathol Lab Med 111 (1987): 953-6</p><p id="ref_47">47. Baguet JP, Tremel F, Fabre M "Chloroquine cardiomyopathy with conduction disorders." Heart 81 (1999): 221-3</p><p id="ref_48">48. Iglesias Cubero G, Rodriguez Reguero JJ, Rojo Ortega JM "Restrictive cardiomyopathy caused by chloroquine." Br Heart J 69 (1993): 451-2</p><p id="ref_49">49. Robberecht W, Bednarik J, Bourgeois P, et al "Myasthenic syndrome caused by direct effect of chloroquine on neuromuscular junction." Arch Neurol 46 (1989): 464-8</p><p id="ref_50">50. Parodi A, Regesta G, Rebora A "Chloroquine-induced neuromyopathy." Dermatologica 171 (1985): 203-5</p><p id="ref_51">51. Nucci A, Queiroz LS, Samara AM "Chloroquine neuromyopathy." Clin Neuropathol 15 (1996): 256-8</p><p id="ref_52">52. Avinazubieta JA, Johnson ES, Suarezalmazor ME, Russell AS "Incidence of myopathy in patients treated with antimalarials. a report of three cases and a review of the literature." Br J Rheumatol 34 (1995): 166-70</p><p id="ref_53">53. Estes ML, Wing-Wilson D, Chou SM, et al "Chloroquine neuromyotoxicity." Am J Med 82 (1987): 447-55</p><p id="ref_54">54. Wasay M, Wolfe GI, Herrold JM, Burns DK, Barohn RJ "Chloroquine myopathy and neuropathy with elevated CSF protein." Neurology 51 (1998): 1226-7</p><p id="ref_55">55. Schirlanzoni A, Mantegazza R, Mora M, et al "Chloroquine myopathy and myasthenia-like syndrome." Muscle Nerve 11 (1988): 114-9</p><p id="ref_56">56. Hearn J, Tiliakos NA "Myasthenia gravis caused by pencillamine and chloroquine therapy for rheumatoid arthritis." South Med J 79 (1986): 1185-6</p><p id="ref_57">57. Winkelman RK, Merwin CF, Brunsting LA "Antimalarial therapy of lupus erythematosus." Ann Intern Med 55 (1961): 772-6</p><p id="ref_58">58. Polano MK, Cats A, van Olden GAJ "Agranulocytosis following treatment with hydroxychloroquine sulphate." Lancet 1 (1965): 1275</p><p id="ref_59">59. Buchanan N "Hypokalaemia and acute chloroquine ingestion." Lancet 347 (1996): 404</p><p id="ref_60">60. Clemessy JL, Borron SW, Baud FJ "Hypokalaemia and acute chloroquine ingestion - reply." Lancet 347 (1996): 404-5</p><p id="ref_61">61. Angel G, Berthelot PG, Rogier C "Hypokalaemia related to acute chloroquine poisoning." Lancet 346 (1995): 1625</p><h2 class="ddc-anchor-offset" id="faq">Frequently asked questions</h2><ul>
<li>An Update: Is hydroxychloroquine effective for COVID-19?</li>
</ul><h2>More about Aralen (chloroquine)</h2><ul class="more-resources-list more-resources-list-general">
<li>During Pregnancy or 
Breastfeeding</li>
<li>Dosage Information</li>
<li>Drug Interactions</li>
<li>Drug class: amebicides</li>
<li>FDA Alerts (2)</li>
</ul><h3>Consumer resources</h3><h3>Professional resources</h3><ul class="more-resources-list more-resources-list-professional">
<li>Prescribing Information</li>
<li data-more-config-id="list-data-resources-professional">... +1 more</li>
</ul><h3>Related treatment guides</h3><ul class="more-resources-list more-resources-list-conditions">
<li>Amebiasis</li>
<li>Malaria</li>
<li>Malaria Prevention</li>
<li>Sarcoidosis</li>
</ul><h2>Further information</h2><p class="ddc-disclaimer">Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.</p><p>Some side effects may not be reported. You may report them to the FDA.</p><p class="ddc-disclaimer-link">Medical Disclaimer</p>